首頁 > 市場調查報告書 > 醫療設備

醫學影像診斷癌症核子醫學

市場調查報告書

商品編碼

1634216

全球粒子治療市場 - 2025 - 2033

Global Particle Therapy Market - 2025 - 2033

出版日期: 2025年01月13日 | 出版商:

DataM Intelligence | 英文 176 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

2024年，全球粒子治療市場規模達13.3億美元，預計2033年將達到25.8億美元，2025-2033年預測期間複合年成長率為7.9%。

粒子療法是一種先進的放射治療形式，利用質子、中子和碳離子等帶電粒子攻擊癌細胞。與使用 X光的典型光子療法不同，粒子療法利用帶電粒子的獨特物理特徵來更精確地傳遞輻射。這種精確度使得最大量的輻射能夠定位在腫瘤部位，同時最大限度地減少對鄰近健康組織的暴露，降低與傳統放射治療相關的副作用和長期後果的風險。

對粒子治療的需求不斷成長是預測期內推動市場的促進因素。癌症病例數量的增加增加了對粒子療法的需求，因為它用於癌症的治療和管理。例如，根據美國國立衛生研究院的數據，到 2023 年，美國預計將出現 1,958,310 例新癌症病例。經過二十年的下降，2014年至2019年，攝護腺癌發生率每年增加3%，新增病例增加9.9萬例。

市場動態：

驅動程式和限制

對粒子治療的需求不斷增加

對粒子治療的需求不斷成長預計將成為全球粒子治療市場成長的重要因素。全球粒子治療市場預計將大幅擴張，這主要是由於癌症盛行率不斷上升、技術進步、最近的上市和批准、戰略合作夥伴關係以及人們意識的提高。粒子療法（包括質子療法和重離子療法）與典型的基於光子的放射療法相比具有多種優勢，包括對健康組織的傷害較小以及長期負面影響較少。這種針對惡性腫瘤的精確性改善了患者的整體生活品質，導致醫療保健從業者和患者越來越傾向於粒子治療。

全球癌症發生率的上升對粒子治療日益成長的需求產生了重大影響。癌症仍然是全世界疾病的主要原因之一。例如，根據世界癌症研究基金會的數據，2022 年包括非黑色素瘤皮膚癌 (NMSC) 在內的癌症病例數為 19,976,499 例。當 NMSC 被消除後，到 2022 年，全球癌症病例數將減少至 18,741,966 例。此外，根據 IARC 的數據，2022 年將新增約 2,000 萬名癌症病例（包括非黑色素瘤皮膚癌 [NMSC]）。據估計，五分之一的男性和女性會在一生中的某個階段罹患癌症。肺癌是 2022 年最常被診斷出的癌症，約佔 250 萬新發病例，即全球每八種惡性腫瘤中就有一種（佔所有癌症的 12.4%）。因此，對有效治療替代方案的需求從未如此強烈。這種不斷上升的發病率凸顯了對改進治療技術的迫切需要，例如粒子療法，其中包括質子和重離子療法，以其精確靶向腫瘤同時對鄰近健康組織造成最小損害而聞名。

技術進步顯著提高了顆粒處理的可及性和有效性。最近的創新包括緊湊且便宜的質子治療設備的出現，這使得在不同的地方安裝更多的治療中心成為可能。這些創新不僅降低了總治療成本，也簡化了經典粒子治療系統的操作複雜性。例如，2024 年 10 月，傑斐遜實驗室宣布與漢普頓大學質子癌症研究所 (HUPCI) 和 Leo Cancer Care 合作，研究質子療法作為更安全的癌症治療選擇的潛力。此次合作旨在利用新技術來提高質子療法的精確度和有效性，質子療法使用高能量質子束來靶向癌症，同時對周圍健康組織造成最小的損害。這項措施尤其重要，因為它的目的是取代依賴鈷 60 等放射性同位素的標準治療方法，這些同位素會帶來固有的放射性危險。

初始成本高

初始成本高等因素預計將阻礙全球粒子治療市場。建立粒子治療中心可能耗資超過 1 億美元，其中包括迴旋加速器或同步加速器等昂貴的設備、特定的屏蔽基礎設施以及確保治療期間患者安全所需的技術。例如，根據國家衛生研究院的數據，粒子治療費用從 10,030 歐元（c 離子：肺癌）到 39,610 歐元（質子：頭頸惡性腫瘤）不等。由於這些重大的資本承諾，許多醫療保健提供者面臨進入壁壘，特別是在資金和醫療保健預算不足的低度開發國家。因此，粒子療法的高昂財務成本限制了其廣泛接受和可從這種創新治療技術中受益的個人的可及性。

有關此報告的更多詳細資訊 - 索取樣本

Particle therapy is an advanced form of radiation treatment that targets cancerous cells with charged particles such as protons, neutrons, and carbon ions. Unlike typical photon-based therapies that use X-rays, particle therapy uses the distinct physical features of charged particles to deliver radiation more precisely. This precision enables the greatest amount of radiation to be localized at the tumor site while minimizing exposure to adjacent healthy tissues, lowering the risk of side effects and long-term consequences associated with traditional radiation therapies.

The increasing demand for particle therapy is the driving factor that drives the market over the forecast period. The increasing number of cancer cases increases the demand for particle therapy since it is used in the treatment and management of cancer. For instance, according to the National Institute of Health, In 2023, the United States is projected to see 1,958,310 new cancer cases. Prostate cancer incidence reached 3% every year from 2014 to 2019, after two decades of reduction, resulting in an additional 99,000 new cases.

Market Dynamics: Drivers & Restraints

Increasing demand for particle therapy

The increasing demand for particle therapy is expected to be a significant factor in the growth of the global particle therapy market. The global particle therapy market is poised for significant expansion, owing mostly to the rising prevalence of cancer, technological advancements, recent launches and approvals, strategic partnerships, and increasing awareness among people. Particle therapy, which includes proton and heavy ion therapies, has several advantages over typical photon-based radiation treatments, including less harm to healthy tissues and fewer long-term negative effects. This precision in targeting malignancies improves patients' overall quality of life, resulting in an increasing preference for particle therapy among both healthcare practitioners and patients.

The rising global incidence of cancer has a substantial impact on the growing need for particle therapy. Cancer remains one of the top causes of sickness worldwide. For instance, According to the World Cancer Research Fund, the number of cancer cases in 2022, including non-melanoma skin cancer (NMSC), was 19,976,499. When NMSCs were eliminated, the global cancer case count was reduced to 18,741,966 in 2022. There were 9,566,825 males and 9,175,141 females. Furthermore, according to the IARC, there will be about 20 million new cancer cases in 2022 (including nonmelanoma skin cancers [NMSCs]). According to estimates, one in every five men and women will get cancer at some point in their lives. Lung cancer was the most often diagnosed cancer in 2022, accounting for about 2.5 million new cases, or one in every eight malignancies globally (12.4% of all cancers). Thus the need for effective treatment alternatives has never been stronger. This rising incidence highlights the critical need for improved therapeutic techniques such as particle therapy, which comprises proton and heavy ion therapies known for their precision in targeting tumors while causing minimal damage to adjacent healthy tissues.

Technological advancements have significantly improved the accessibility and efficacy of particle treatment. Recent innovations include the advent of compact and less expensive proton therapy devices, which made it possible for the installation of more treatment centers in diverse places. These innovations not only lower total treatment costs but also simplify the operational complexity involved with classic particle therapy systems. For instance, in October 2024, Jefferson Lab announced that it is collaborating with the Hampton University Proton Cancer Institute (HUPCI) and Leo Cancer Care to study the potential of proton therapy as a safer cancer treatment option. This collaboration intends to use new technology to improve the precision and effectiveness of proton therapy, which uses high-energy proton beams to target cancers while causing minimal damage to surrounding healthy tissues. This initiative is particularly significant since it aims to replace standard treatments that rely on radioactive isotopes like cobalt-60, which pose inherent radiological dangers.

High initial costs

Factors such as high initial costs are expected to hamper the global particle therapy market. Setting up a particle therapy center can cost more than USD 100 million, which includes expensive equipment such as cyclotrons or synchrotrons, specific shielding infrastructure, and the technologies required to ensure patient safety during treatment. For instance, according to the National Institute of Health, Particle treatment expenses vary from Euro 10,030 (c-ion: lung cancer) to Euro 39,610 (proton: head & neck malignancies). Many healthcare providers face a barrier to entry as a result of these significant capital commitments, particularly in underdeveloped countries with inadequate funding and healthcare budgets. As a result, the high financial cost of particle therapy limits its widespread acceptance and accessibility to individuals who could benefit from this innovative therapeutic technique.

For more details on this report - Request for Sample

Segment Analysis

The global particle therapy market is segmented based on type, system, application, cancer type, end-user, and region.

Proton Therapy segment is expected to dominate the global particle therapy market share

The proton therapy segment is anticipated to dominate the global particle therapy market owing to its unique advantages, technological advancements, and increasing acceptance among healthcare providers and patients. Proton therapy uses charged particles, or protons, to deliver targeted radiation to malignant tumors while limiting damage to surrounding healthy tissues. This accuracy is especially useful for treating cancers near important organs, such as brain tumors or pediatric cancers, where conventional radiation therapies may represent a larger risk of collateral damage. As more people become aware of the benefits of proton therapy, demand for its utilization increases.

The increasing prevalence of cancer, as well as technological improvements that have made proton therapy more accessible and effective, are driving the segment's rise. Compact proton therapy devices and advanced imaging techniques have improved treatment delivery, resulting in more efficient patient management and better clinical outcomes. These technological advancements are critical in resolving the limits of standard photon treatment, hence strengthening proton therapy's market position.

Furthermore, the growing number of proton therapy centers worldwide contributes to the segment's dominance. Major investments and launches by healthcare organizations and governments have contributed to financing the establishment of new centers equipped with modern proton treatment devices. For instance, in February 2024, the University of Leeds initiated a trial supported by the National Institute for Health and Care Research (NIHR) and the Medical Research Council (MRC) to look into a possible treatment for brain cancer. A new clinical trial concentrating on proton beam therapy for brain cancer began in the United Kingdom, representing a significant leap in cancer treatment choices. This trial, called APPROACH (Analysis of Proton vs Photon Radiotherapy in Oligodendroglioma and Assessment of Cognitive Health), seeks to determine whether proton beam therapy can lessen long-term side effects when compared to regular photon radiotherapy. The experiment is aimed specifically at patients diagnosed with oligodendroglioma, a kind of brain cancer that affects roughly 350 people in the UK each year.

Geographical Analysis

North America is expected to hold a significant position in the global particle therapy market share

North America is anticipated to hold a significant portion of the global particle therapy market owing to the rising prevalence of cancer, technological advancements, recent product launches and approvals, strategic partnerships, and increasing awareness. The higher prevalence of cancer in North America also contributes to the increased demand for advanced treatment solutions. This alarming trend highlights the critical need for effective treatment alternatives, encouraging healthcare experts and patients to look into sophisticated medicines like particle therapy. As more patients become aware of the benefits of proton therapy, they are turning to this tailored treatment technique, which allows for more precise tumor targeting while avoiding damage to adjacent healthy tissues.

For instance, according to an article published by the National Institute of Health in 2024, the United States is projected to see 2,001,140 new cancer cases. North America's dominance in the particle therapy segment is due to technological breakthroughs. The emergence of small proton therapy systems has transformed the scene by making treatment more accessible and affordable. These systems require less physical space than traditional setups, allowing more hospitals and clinics to use proton therapy in their cancer treatment options. Furthermore, advances such as pencil-beam scanning and real-time imaging technology improve the precision of proton treatment, allowing practitioners to deliver targeted radiation more effectively while reducing damage to adjacent healthy tissues. This level of accuracy is especially useful for treating tumors near essential structures, such as those found in pediatric patients or brain cancers.

For instance, in December 2023, Nationwide Children's Hospital and The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) have announced the opening of a $100 million, 55,000-square-foot proton therapy center, the first treatment facility in central Ohio to provide this highly targeted form of radiation therapy for the treatment of complex tumors that cannot be removed surgically.

Asia Pacific is growing at the fastest pace in the global particle therapy market

One of the key drivers of this expansion is Asia Pacific's huge and expanding population, which contributes to an increased incidence of oncological disorders. As cancer incidence continues to increase across this diverse region, the need for advanced treatment modalities like particle therapy becomes increasingly critical.

For instance, according to the National Institute of Health, the estimated number of cancer cases in India in 2022 is 14,61,427 (crude rate: 100.4 per 100,000). In India, one in every nine people is likely to develop cancer over their lifetime. Males and females were more likely to acquire lung and breast cancers, respectively. This alarming trend underscores the urgent need for effective treatment options that can address the unique challenges posed by various types of cancer prevalent in the region.

Competitive Landscape

The major global players in the global particle therapy market include IBA Worldwide, Siemens Healthcare Private Limited, Hitachi High-Tech Corporation, Mevion Medical Systems, Provision Healthcare, Optivus Proton Therapy, Inc., Sumitomo Heavy Industries, Ltd., ProTom International, B dot Medical Inc., Atlas Copco Group among others.

Emerging Players

Panacea, Terapet, and P-Cure among others

Key Developments

In September 2024, The Tata Memorial Centre (TMC) launched in-house research initiatives focused on maximizing the use of proton beam therapy for cancer treatment, marking a significant advancement in oncology care in India. This initiative coincides with the one-year anniversary of TMC's proton therapy facility, which was inaugurated to provide cutting-edge radiation treatment options for both pediatric and adult cancer patients. The facility at TMC is equipped with state-of-the-art technology, including the latest Pencil Beam Scanning (PBS) capabilities and Intensity Modulated Proton Therapy (IMPT).

Why Purchase the Report?

Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
Real-world Evidence: Integrates patient feedback and data into product development for improved outcomes.
Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
Post-market Surveillance: Uses post-market data to enhance product safety and access.
Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global particle therapy market report delivers a detailed analysis with 60+ key tables, more than 50 visually impactful figures, and 176 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2024

Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
Supply Chain: Distribution and Supply Chain Managers.
Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
Academic & Research: Academic Institutions.

1. Methodology and Scope

1.1. Research Methodology
1.2. Research Objective and Scope of the Report

2. Definition and Overview

3. Executive Summary

3.1. Snippet by Technology
3.2. Snippet by Cancer Type
3.3. Snippet by Application
3.4. Snippet by End-User
3.5. Snippet by Region

4. Dynamics

4.1. Impacting Factors
- 4.1.1. Drivers
- 4.1.2. Increasing Demand for Particle Therapy
- 4.1.3. Restraints
- 4.1.4. High Initial Costs
- 4.1.5. Opportunity
- 4.1.6. Impact Analysis

5. Industry Analysis

5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Reimbursement Analysis
5.6. Patent Analysis
5.7. SWOT Analysis
5.8. DMI Opinion

6. By Type

6.1. Introduction
- 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 6.1.2. Market Attractiveness Index, By Type
6.2. Proton Therapy*
- 6.2.1. Introduction
- 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
6.3. Heavy Ion Therapy

7. By System

7.1. Introduction
- 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 7.1.2. Market Attractiveness Index, By System
7.2. Single Room Systems*
- 7.2.1. Introduction
- 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Multi-room Systems

8. By Application

8.1. Introduction
- 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 8.1.2. Market Attractiveness Index, By Application
8.2. Treatment*
- 8.2.1. Introduction
- 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.3. Clinical Research

9. By Cancer Type

9.1. Introduction
- 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 9.1.2. Market Attractiveness Index, By Cancer Type
9.2. Pediatric Cancer*
- 9.2.1. Introduction
- 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Breast Cancer
9.4. Lung Cancer
9.5. Neck Cancer
9.6. Others

10. By End User

10.1. Introduction
- 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End User
- 10.1.2. Market Attractiveness Index, By End User
10.2. Hospitals*
- 10.2.1. Introduction
- 10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
10.3. Cancer Research Institutes
10.4. Diagnostic Centres

11. By Region

11.1. Introduction
- 11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
- 11.1.2. Market Attractiveness Index, By Region
11.2. North America
- 11.2.1. Introduction
- 11.2.2. Key Region-Specific Dynamics
- 11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.8.1. U.S.
  - 11.2.8.2. Canada
  - 11.2.8.3. Mexico
11.3. Europe
- 11.3.1. Introduction
- 11.3.2. Key Region-Specific Dynamics
- 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.3.8.1. Germany
  - 11.3.8.2. U.K.
  - 11.3.8.3. France
  - 11.3.8.4. Spain
  - 11.3.8.5. Italy
  - 11.3.8.6. Rest of Europe
11.4. South America
- 11.4.1. Introduction
- 11.4.2. Key Region-Specific Dynamics
- 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.8.1. Brazil
  - 11.4.8.2. Argentina
  - 11.4.8.3. Rest of South America
11.5. Asia-Pacific
- 11.5.1. Introduction
- 11.5.2. Key Region-Specific Dynamics
- 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
- 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.5.8.1. China
  - 11.5.8.2. India
  - 11.5.8.3. Japan
  - 11.5.8.4. South Korea
  - 11.5.8.5. Rest of Asia-Pacific
11.6. Middle East and Africa
- 11.6.1. Introduction
- 11.6.2. Key Region-Specific Dynamics
- 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Type
- 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By System
- 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Application
- 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Cancer Type
- 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

12. Competitive Landscape

12.1. Competitive Scenario
12.2. Market Positioning/Share Analysis
12.3. Mergers and Acquisitions Analysis

13. Company Profiles

13.1. IBA Worldwide*
- 13.1.1. Company Overview
- 13.1.2. Product Portfolio and Description
- 13.1.3. Financial Overview
- 13.1.4. Key Developments
13.2. Siemens Healthcare Private Limited
13.3. Hitachi High-Tech Corporation
13.4. Mevion Medical Systems
13.5. Provision Healthcare
13.6. Optivus Proton Therapy, Inc.
13.7. Sumitomo Heavy Industries, Ltd.
13.8. ProTom International
13.9. B dot Medical Inc.
13.10. Atlas Copco Group

LIST NOT EXHAUSTIVE